# Orchard Therapeutics plc (ORTX)

Source: https://www.quantisnow.com/company/ORTX
Generated: 2026-11-12T23:13:11.598Z

- Ticker: ORTX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2018
- Website: orchard-tx.com

## About

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

## Latest ORTX news and filings

- 2024-05-07 11:00 UTC [Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024](https://www.quantisnow.com/insight/orchard-therapeutics-announces-multiple-presentations-at-asgct-2024-5464477)
- 2024-05-03 11:00 UTC [Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List](https://www.quantisnow.com/insight/orchard-therapeutics-co-founder-and-chief-executive-officer-dr-bobby-gaspar-5456597)
- 2024-03-20 11:00 UTC [Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy](https://www.quantisnow.com/insight/orchard-therapeutics-outlines-us-launch-plans-for-lenmeldy-atidarsagene-autotemcel-5356783)
- 2024-03-18 19:41 UTC [Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.](https://www.quantisnow.com/insight/orchard-therapeutics-receives-fda-approval-of-lenmeldy-atidarsagene-autotemcel-the-5350986)
- 2024-02-22 13:00 UTC [ORI Capital Raises $260 Million for Second Life Sciences Fund](https://www.quantisnow.com/insight/ori-capital-raises-260-million-for-second-life-sciences-fund-5282963)
- 2024-02-15 02:05 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Orchard Therapeutics plc](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-orchard-therapeutics-plc-5265808)
- 2024-02-14 23:35 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-orchard-therapeutics-plc-amendment-5265478)
- 2024-02-12 17:03 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-orchard-therapeutics-plc-amendment-5249364)
- 2024-02-09 14:28 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-orchard-therapeutics-plc-amendment-5244350)
- 2024-02-09 00:01 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-orchard-therapeutics-plc-amendment-5243078)
- 2024-02-05 19:39 UTC [SEC Form 15-12G filed by Orchard Therapeutics plc](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-orchard-therapeutics-plc-5229702)
- 2024-02-05 12:00 UTC [Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome](https://www.quantisnow.com/insight/orchard-therapeutics-announces-first-patient-randomized-in-registrational-trial-of-5228332)
- 2024-02-02 12:00 UTC [Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium](https://www.quantisnow.com/insight/orchard-therapeutics-announces-multiple-presentations-at-the-20th-annual-worldsymposium-5225021)
- 2024-01-31 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Orchard Therapeutics plc](https://www.quantisnow.com/insight/sec-form-effect-filed-by-orchard-therapeutics-plc-5218500)
- 2024-01-31 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Orchard Therapeutics plc](https://www.quantisnow.com/insight/sec-form-effect-filed-by-orchard-therapeutics-plc-5218498)
- 2024-01-25 12:16 UTC [Market Chatter] [Orchard Therapeutics Reached An Agreement With The Beneluxa Initiative On Pharmaceutical Policy (Beneluxa) Enabling Reimbursed Access To Libmeldy= (atidarsagene autotemcel) Approved For The Treatment Of Early-onset Metachromatic Leukodystrophy (MLD)](https://www.quantisnow.com/insight/orchard-therapeutics-reached-an-agreement-with-the-beneluxa-initiative-on-5206345)
- 2024-01-25 12:00 UTC [Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy](https://www.quantisnow.com/insight/orchard-therapeutics-announces-agreement-with-the-beneluxa-consortium-enabling-reimbursed-5206245)
- 2024-01-24 22:34 UTC [SEC Form 4] [SEC Form 4 filed by Secor Alicia](https://www.quantisnow.com/insight/sec-form-4-filed-by-secor-alicia-5205664)
- 2024-01-24 22:29 UTC [SEC Form 4] [Geraghty James A returned 44,391 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/geraghty-james-a-returned-44391-units-of-ordinary-shares-to-5205655)
- 2024-01-24 22:27 UTC [SEC Form 4] [Thomas Frank E returned 92,081 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/thomas-frank-e-returned-92081-units-of-ordinary-shares-to-5205645)
- 2024-01-24 22:25 UTC [SEC Form 4] [Rowland Charles A Jr returned 12,294 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/rowland-charles-a-jr-returned-12294-units-of-ordinary-shares-5205612)
- 2024-01-24 22:20 UTC [SEC Form 4] [Beck Joanne T. returned 9,294 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/beck-joanne-t-returned-9294-units-of-ordinary-shares-to-5205480)
- 2024-01-24 22:17 UTC [SEC Form 4] [Dunoyer Marc returned 37,179 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/dunoyer-marc-returned-37179-units-of-ordinary-shares-to-the-5205476)
- 2024-01-24 22:18 UTC [SEC Form 4] [Gaspar Bobby returned 366,158 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/gaspar-bobby-returned-366158-units-of-ordinary-shares-to-the-5205475)
- 2024-01-24 22:16 UTC [SEC Form 4] [SEC Form 4 filed by Altschuler Steven](https://www.quantisnow.com/insight/sec-form-4-filed-by-altschuler-steven-5205465)
- 2024-01-24 22:16 UTC [SEC Form 4] [SEC Form 4 filed by Curnutte John T](https://www.quantisnow.com/insight/sec-form-4-filed-by-curnutte-john-t-5205460)
- 2024-01-24 21:41 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Orchard Therapeutics plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-orchard-therapeutics-plc-5205292)
- 2024-01-24 21:39 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Orchard Therapeutics plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-orchard-therapeutics-plc-5205279)
- 2024-01-24 21:37 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Orchard Therapeutics plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-orchard-therapeutics-plc-5205266)
- 2024-01-24 21:35 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Orchard Therapeutics plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-orchard-therapeutics-plc-5205251)
- 2024-01-24 21:34 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Orchard Therapeutics plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-orchard-therapeutics-plc-5205228)
- 2024-01-24 21:30 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Orchard Therapeutics plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-orchard-therapeutics-plc-5205191)
- 2024-01-24 21:28 UTC [SEC Form POS AM filed by Orchard Therapeutics plc](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-orchard-therapeutics-plc-5205136)
- 2024-01-24 21:25 UTC [SEC Form POS AM filed by Orchard Therapeutics plc](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-orchard-therapeutics-plc-5205119)
- 2024-01-24 21:17 UTC [SEC Form 8-K] [Orchard Therapeutics plc filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/orchard-therapeutics-plc-filed-sec-form-8-k-termination-of-a-5205032)
- 2024-01-24 13:27 UTC [SEC Form 25-NSE filed by Orchard Therapeutics plc](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-orchard-therapeutics-plc-5203362)
- 2024-01-24 10:34 UTC [Market Chatter] [Kyowa Kirin Completes Acquisition Of Orchard Therapeutics](https://www.quantisnow.com/insight/kyowa-kirin-completes-acquisition-of-orchard-therapeutics-5202780)
- 2024-01-24 10:00 UTC [Mergers & Acquisitions] [Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases](https://www.quantisnow.com/insight/kyowa-kirin-successfully-completes-acquisition-of-orchard-therapeutics-a-global-5202764)
- 2024-01-22 21:10 UTC [SEC Form 8-K] [Orchard Therapeutics plc filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/orchard-therapeutics-plc-filed-sec-form-8-k-other-events-5199017)
- 2024-01-17 13:00 UTC [INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors](https://www.quantisnow.com/insight/invo-bioscience-files-s-4-registration-and-preliminary-joint-proxy-statements-5190146)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ORTX
- Earnings history: https://www.quantisnow.com/earnings/ORTX
- Dividend history: https://www.quantisnow.com/dividends/ORTX
- Insider transactions: https://www.quantisnow.com/insiders/ORTX
- Options chain: https://www.quantisnow.com/options/ORTX
- SEC 8-K filings only: https://www.quantisnow.com/company/ORTX/8-k
- RSS and alerts for ORTX: https://www.quantisnow.com/docs/rss-feeds.md